Neurology® Podcast

1) Stroke thrombolysis and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Atte Meretoja about her paper on reducing in-hospital delay. Dr. Jennifer Fugate is reading our e-Pearl of the week about mytonic dystrophy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Reisa Sperling about her plenary session on molecular and functional imaging detection of preclinical Alzheimer disease. The participants had nothing to disclose except Drs. Meretoja, Fugate, Espay and Sperling.Dr. Meretoja has served as a consultant for Boehringer Ingelheim, and has received honoraria from Boehringer Ingelheim for speaking at educational symposia, travel expenses from H Lundbeck A/S, and research support from Sigrid Juselius Foundation, Biomedicum Helsinki Foundation, Instrumentarium Science Foundation, Yrjo Jahnsson Foundation, Paivikki and Sakari Sohlberg Foundation, Maire Taponen Foundation, Finnish-Norwegian Medical Foundation and Emil Aaltonen Foundation.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Sperling received a speaker honorarium from Pfizer Inc.; serves on the editorial board of Alzheimer¹s disease and Associated Disorders; has served as a consultant for Roche, Janssen, Pfizer Inc, Bayer Schering Pharma, Eisai Inc., Satori, Kyowa Hakko Kirin, Bristol-Myers Squibb and Avid Radiopharmaceuticals, (unpaid); has received research support from Janssen, and Bristol-Myers Squibb, NIH/NIA, Alzheimer¹s Association, American Health Assistance Foundation, and an Anonymous Foundation.

1) Anterior disconnection syndrome and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Drs. Ana Pereira and Alvardo Pascual-Leone about their paper on the anterior disconnection syndrome. Dr. Jennifer Fugate is reading our e-Pearl of the week about normal pressure hydrocephalus. In the next part of the podcast Dr. Alberto Espay interviews Dr. Richard Bedlack about his plenary session on contemporary clinical issues. The participants had nothing to disclose except Drs. Waugh, Pascual-Leone, Fugate, Espay and Bedlack.Dr. Waugh serves as an editorial board member of the Journal of Pediatric Biochemistry.Dr. Pascual-Leone serves on the scientific advisory board for Nexstim, NeoSync, Starlab, Neuronix, Allied minds and NovaVision, inc.; serves as an Associate Editor for European Journal of Neuroscience and Frontiers in Neuroscience; is listed as co-inventor in several patents related to real-time integration of TMS with EEG and functional imaging; receives research support from Nexstim, Neuronix, NIH, The Michael J. Fox Foundation, Berenson-Allen Foundation and RJG Family Foundation.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Bedlack serves on the scientific advisory board DSMB for the ceftriaxone ALS trial; serves on the speakers' bureau of Pfizer Inc, Eli Lilly and Company, Athena Diagnostics and Avanir Pharmaceuticals; is a consultant for Avanir Pharmaceuticals, Sanofi-aventis, Athena Diagnostics and UCB; receives research support from UCB, Biogen, Cytokinetics, Neuraltis and NIH. His clinic is sponsored by the ALS Association; and he is also involved in conducting clinical trials.

1) Patients treated with antiepileptic drugs and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. John Wark and Prof. Terry O' Brien about their paper on falls and fractures in patients treated with antiepileptic drugs. Dr. Jennifer Fugate is reading our e-Pearl of the week about Duchenne muscular dystrophy. In the next part of the podcast Dr. Alberto Espay continues his interview with Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with interviews from other plenary sessions. All participants have disclosures.Dr. Fountain serves as an editorial board member of Epilepsy Currents, serves on the Board of Directors, National Association of Epilepsy Centers, receives travel reimbursement from UCB; performs EEG interpretation for the University of Virginia (10% effort); receives research support from UCB, Sepracor Inc., Medtronic, Inc., Vertex Pharmaceuticals and NeuroPace; and is funded by the NIH.Dr. Wark serves on the scientific advisory boards for Amgen/GlaxoSmithKline, Novartis and LactoPharma; serves as a specialist editor of Clinical Science; editorial board members of Osteoporosis International and Journal of Osteoporosis; serves on the speakers' bureau of Servier, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; serves on the speakers' bureau of Servier, Amgen, Novartis, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; received travel reimbursement from Servier; is a consultant for Vactec and AstraZeneca; performs bone density testing for the Royal Melbourne Hospital (10% effort); receives royalties from the publication of the book Physical Activity and Bone Health; receives research support from Novartis, UCB, Sanofi-aventis, Eli Lilly and Company, Monash University, LaTrobe University, National Health and Medical Research Council of Australia, Victorian Cancer Agency and ANZ Trustees.Prof. O'Brien served as editorial board members of Epilepsia, Journal of Clinical Neuroscience and Epilepsy and Behavior; serves on the speakers' bureaus of UCB, Sanofi-aventis and SiGen and receives research support from UCB, Sanofi-aventis Jansen-Cilag, Royal Melbourne Hospital Neuroscience Foundation and Epilepsy Research Foundation and is funded by the NIH and NHMRC.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.

1) Bleeding risk after stroke thrombolysis and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Michael Knoflach about his paper on an increased bleeding risk after stroke thrombolysis. Dr. Jennifer Fugate is reading our e-Pearl of the week about hummingbird sign in PSP. In the next part of the podcast Dr. Alberto Espay interviews Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with our interview with Drs. Titulaer and Vincent. The participants had nothing to disclose except Drs. Kissela, Kiechl, Fugate, Espay and Mehler.Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH, and provides medico-legal reviews.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.

Vitamins & Neurology

1) Progesterone versus placebo therapy for women with epilepsy and 2) Topic of the month: Memory. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Chenjie Xia interviews Dr. Andy Herzog about his paper on progesterone versus placebo therapy for women with epilepsy. Dr. Stacey Clardy is reading our e-Pearl of the week about myotonia congenita. In the next part of the podcast Dr. Ted Burns interviews Dr. Dean Buonomano about bedside testing of memory. The participants had nothing to disclose except Drs. Herzog, Clardy, Burns and Buonomano.Dr. Herzog serves as an editorial board member of Epilepsy & Behavior.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Buonomano receives royalties from the publication of the book Brain Bugs: How the brain's flaws shape our lives.

1) Measures of health-related quality of life and 2) Topic of the month: Memory. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. David Cella about his paper on measures of health-related quality of life. Dr. Stacey Clardy is reading our e-Pearl of the week about frontotemporal dementia. In the next part of the podcast Dr. Ted Burns interviews Dr. Dean Buonomano about major categories of memory. Next week they will discuss bedside testing of memory. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Cella serves on the scientific advisory boards of the Moffitt Cancer Center, NCI Symptom Management and Health-Related Quality of Life (SxQOL) Steering Committee, serves as Associate Editor of The Journal of Supportive Oncology; is a consultant for Pfizer Inc, Genetech, Inc., Novartis, Bayer Schering Pharma, and GlaxoSmithKline; receives royalties from Up-to-Date annual review of Quality of life measures; receives research support from Pfizer Inc, Genetech, Inc., Novartis, Bayer Schering Pharma, GlaxoSmithKline and AVEO Pharmaceuticals, Inc.; and is funded by the NIH.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Buonomano receives royalties from the publication of the book Brain Bugs: How the brain's flaws shape our lives.

Clinical Diagnostic Reasoning and Physician Cognitive Errors

1) Cognitive effects of one season of head impacts 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Thomas McAllister about his paper on cognitive effects of one season of head impacts. Dr. Jennifer Fugate is reading our e-Pearl of the week about Hashimoto encephalopathy. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about preclinical Alzheimer disease. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. All participants have disclosures.Dr. Goodkin serves on the scientific board for Tuberous Sclerosis Alliance and CURE; serves on the editorial board for Neurology and Surgical Neurology International; received royalties for an entry in Up-to-date entitled: The choking game and other strangulation activities in children and adolescents and is funded by NIH grants.Dr. McAllister is funded by NIH grants.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) Small fiber neuropathy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steve Waxman about his paper on small fiber neuropathy. Dr. Jennifer Fugate is reading our e-Pearl of the week about diffusion-weighted imaging. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about other biomarkers for mild cognitive impairment and Alzheimer disease. Next week they will discuss preclinical Alzheimer disease. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Waxman serves on the editorial boards of Clinical Neuroscience, The Neurologist, Neurobiology of Disease, Clinical Neurology and Neurosurgery, SYNAPSE, Molecular Neurobiology, Clinical Neuroscience Research, Neuron-Glia Biology, Neurotherapeutics, Trends in Molecular Medicine, Molecular Pain and Channels; served on the editorial board Journal of Neurotrauma; serves on the scientific advisory board for Brain and Nature Reviews Neurology; Editor-in-Chief of The Neuroscientist and Neuroscience Letters; Editor of The Journal of Physiology; Section Head Multiple Sclerosis, Faculty of 1000 Medicine; is or has been a consultant for Cardiome Pharmaceutical, Bristol-Myers Squibb, Vertex Pharmaceutical, ChromaCell and DaiNippon Sumitomo Pharmaceuticals; receives research support from Pfizer Inc., The Erythromelalgia Association and Department of Veterans Affairs; holds stock options in SITE ONE Research for serving on its Advisory Board and is listed as an inventor for a patent held by Yale University on the Invention of sodium channel NaV1.9.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) Newly diagnosed epilepsy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jen Langer interviews Prof. Martin Brodie about his paper on newly diagnosed epilepsy. Dr. Jennifer Fugate is reading our e-Pearl of the week about nocturnal wandering in adults. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about imaging modalities for diagnosis of mild cognitive impairment and Alzheimer disease. Over the next two weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. The participants had nothing to disclose except Prof. Brodie, Drs. Fugate, Burns and Morris.Prof. Brodie serves on the editorial boards of Seizure, Epilepsy & Behavior, CNS Drugs and Acta Neurologica Scandinavia; serves on scientific advisory boards for Pfizer Inc, UCB, Eisai Inc., GlaxoSmithKline, Novartis, Sanofi-aventis, Upsher-Smith Laboratories, Inc. and Lundbeck Inc; has received funding for travel from UCB; serves as a consultant for Eisai Inc.; serves on speakers' bureaus for UCB, GlaxoSmithKline, and Eisai Inc.; and has received research support from GlaxoSmithKline, and Eisai Inc.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) A case of Necrotizing myopathy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Mammen interviews Prof. Michael Hanna about his paper on necrotizing myopathy. Dr. Jennifer Fugate is reading our e-Pearl of the week about unilateral clubbing in hemiplegia. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of Alzheimer disease. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures.Dr. Mammen has served as an expert witness for trials in 2010 and 2011; receives revenue for a patent on anti-HMGCR antibody detection technology; and received honoraria for Grand Round presentations at several universities.Prof. Hanna receives research funding from the Medical Research Council, MRC Center grant (G0601943), from the Muscular Dystrophy Campaign and the Consortium for Clinical Investigation of Neurological Channelopathies (CINCH) NIH grant U54 NS059065. M.G. Hanna provides the UK national patient referral center for skeletal muscle channelopathies funded by the UK Department of Health National Commissioning Group. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

Neuromuscular Junction Disorders

1) Simultaneous PML-IRIS in MS and 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Igor Koralnik about his paper on simultaneous PML-IRIS in an MS patient. Dr. Jennifer Fugate is reading our e-Pearl of the week about traumatic brain injury. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of mild cognitive impairment. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures.Dr. Keegan serves as eMedicine Chief Editor and is a consultant for Bionest and Novartis. Dr. Koralnik serves on the editorial board of the Journal of NeuroVirology; served on the scientific advisory boards for Hoffman-La Roche Inc., GlaxoSmithKline and Merck Serono; receives royalties from UpToDate, Inc.; has served as a consultant for Bristol-Myers Squibb, Ono Pharmaceuticals Co. LTD., Merck Serone, Hoffman-La Roche Inc., GlaxoSmithKline, Perseid Therapeutic LLC; Vertex Pharmaceuticals; and Johnson & Johnson; receives research support from NIH; and has received research support from Biogen Idec and the National Multiple Sclerosis Society.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) Evidence-based guideline updates on episodic migraine prevention and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen D. Silberstein and Starr Holland on the guideline updates about treatments for episodic migraine prevention in adults. Dr. Chafic Karam is reading our e-Pearl of the week about scapular winging. In the next part of the podcast Dr. Ted Burns interviews Dr. Lisa Davis about her recent paper titled: Clinical strategies for managing the overweight neurology patient published in the March Neurology Clinical Practice Journal. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Silberstein serves on scientific advisory boards for AGA Medical Corporation, Allergan, Inc., Amgen, CAPNIA, Coherex Medical, GlaxoSmithKline, Iroko Pharmaceuticals, LLC, Eli Lilly and Company, MAP Pharmaceuticals, Inc., Medtronic, Inc., Merck Serono, Neuralieve Inc., the NIH/NINDS, NuPathe Inc., Pfizer Inc, and St. Jude Medical; serves on the editorial boards of Cephalalgia and Current Pain and Headache Reports; serves on the speakers' bureaus for Allergan, Inc., Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck Serono; serves as a consultant for Amgen, Nautilus, Inc., Novartis, Opti-Nose, and Zogenix; receives publishing royalties for Wolff's Headache, 8th edition (Oxford University Press, 2009) and Handbook of Headache (Cambridge University Press, 2010); his employer receives research support from Allergan, Endo, GlaxoSmithKline, MAP, Merck Serono, the NIH/NINDS, Novartis, and Neurolieve; receives research support from the American Headache Society and the International Headache Society.Dr. Holland serves as a consultant for MAP Pharmaceuticals, Inc.; receives research support from Albert Einstein College of Medicine and the American Headache Society.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Davis serves as a consultant for Medifast, Inc. and the Coleman Research Group and is a shareholder in Medifast, Inc.

1) Antidepressants in Parkinson disease and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Barrett interviews Dr. Irene Richard about her paper on antidepressants in Parkinson disease. Dr. Chafic Karam is reading our e-Pearl of the week about migraine without aura. In the next part of the podcast Dr. Brett Kissela interviews Dr. Mitch Elkind about stroke and obesity. Next week, Dr. Burns will interview Dr. Lisa Davis about her recent paper published in the March Neurology Clinical Practice Journal. The participants had nothing to disclose except Drs. Richard, Karam, Kissela, and Elkind.Dr. Richard serves on a scientific advisory board for the Michael J. Fox Foundation; has received a speaker honorarium from Teva Pharmaceutical Industries Ltd.; and receives/has received research support from Neurologix, Inc., Eli Lilly and Company, the NIH/NINDS, Cornell University, and the Michael J. Fox Foundation.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH, and provides medico-legal reviews.Dr. Elkind serves as the Associate Editor of the Neurology® Resident and Fellow Section, serves on an event adjudication committee for Jarvik Heart, receives research support from the NIH, diaDexus, Inc. Sanofi-Aventis, serves on the New York City and Founders Affiliate Boards for the American Heart Association, and has served as a consultant in stroke litigation-legal proceedings.

1) Developing epilepsy after febrile seizures and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Levy Sander about his paper on developing epilepsy after febrile seizures. Dr. Chafic Karam is reading our e-Pearl of the week about neuromyelitis optica. In the next part of the podcast Dr. Ted Burns interviews Dr. Jeff Burns about the link between dementia and obesity. Next week, Dr. Brett Kissela will interview Dr. Mitch Elkind about stroke and obesity. The participants had nothing to disclose except Prof. Sander, Drs. Karam, Ted Burns, and Jeff Burns.Prof. Sander serves on scientific advisory boards for GlaxoSmithKline, Eisai Inc., ViroPharma Incorporated, and UCB; has received funding for travel from UCB and Janssen; serves on the editorial boards of Lancet Neurology, Epileptic Disorders, and Epilepsia; serves on the speakers' bureaus of UCB and GlaxoSmithKline; received research support from UCB (institutional), the NIH, CBRC, European Union Seventh Framework Programme, Wellcome Trust, National Epilepsie Fonds Nederland, and The Brain Research Trust; and his current post is endowed by the UK Epilepsy Society. Dr. Karam serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.

1) Long term remission in CIDP and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Filip Eftimov about his paper on long term remission in CIDP. Dr. Chafic Karam is reading our e-Pearl of the week about acute basilar artery occlusion. In the next part of the podcast Dr. Ted Burns interviews Dr. Beau Bruce about obesity in Idiopathic intracranial hypertension. Drs. Burns & Kissela with interview others about obesity and the neurology patient. The participants had nothing to disclose except Drs. Burns, Eftimov, Karam, and Bruce.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Eftimov received payment from Sanquin Blood Supply Foundation for a single lecture to nurses providing home-care immunoglobulin therapy.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bruce receives research support as recipientof AAN/AANF Practice Research Fellowship and is funded by NIH grants UL1-RR025008 & KL2-RR025009.

Evaluation of dizziness in a patient.

1) Evidence-based guideline on intravenous immunoglobulin and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Huned Patwa about his paper on evidence-based guideline on intravenous immunoglobulin. Dr. Stacey Clardy is reading our e-Pearl of the week about chronic migraine prophylaxis. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about additional topics from their books and columns not previously discussed. The participants had nothing to disclose except Drs. Clardy, Burns, Groopman and Hartzband.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Patwa was an investigator in the ICE trial comparing IGIV with placebo for CIDP.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

1) Lamotrigine and aseptic meningitis and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michaela Tegan Chatman interviews Drs. Simms, Kortepeter and Avigan about their paper on lamotrigine and aseptic meningitis. Dr. Stacey Clardy is reading our e-Pearl of the week about pregnancy on the course of neuromyelitis optica. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about risk-benefit ratios. Next week, Dr. Burns will interview Drs Groopman and Hartzband about additional topics from their books and columns not previously discussed. The participants had nothing to disclose except Drs. Simms, Kortepeter, Avigan, Clardy, Burns, Groopman and Hartzband.Dr. Simms is employed at U.S. Food and Drug Administration. Dr. Kortepeter is employed at U.S. Food and Drug Administration. Dr. Avigan is employed at U.S. Food and Drug Administration. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

1) Cognition in the minimally-conscious state and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Thomas Cochrane interviews Dr. Damian Cruse about his paper on etiology and covert cognition in the minimally-conscious state. Dr. Stacey Clardy is reading our e-Pearl of the week about Moyamoya disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about cognitive errors or biases that can influence our ability to diagnose. Next week, Dr. Burns will interview Drs Groopman and Hartzband about risk-benefit ratios. The participants had nothing to disclose except Drs. Cochrane, Cruse, Clardy, Burns, Groopman and Hartzband.Dr. Cochrane received royalties from the publication of the book First Aid for the Boards: Neurology.Dr. Cruse has received research support from Medical Research Council UK and the Canada Excellence Research Chair Program.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

1) AAN policy on pharmaceutical and device industry support and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mr. John Hutchins about his paper on AAN policy on pharmaceutical and device industry support. Dr. Stacey Clardy is reading our e-Pearl of the week about CSF biomarker in Alzheimer disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about clinical diagnostic reasoning and cognitive errors. Over the following weeks, Dr. Burns will interview Drs Groopman and Hartzband on an additional number of topics with week two about cognitive errors or biases that can influence our ability to diagnose. The participants had nothing to disclose except Mr. Hutchins, Drs. Burns, Clardy, Groopman and Hartzband.Mr. Hutchins is currently the Associate General Counsel of the American Academy of Neurology and General Councel of the American Academy of Neurology Foundation.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

Chafic Karam interviewing Mark Kupersmith about selected neuro-ophthalmology topics originally posted October 2011.

1) Fingolimod-associated macular edema and 2) Topic of the month: Paraneoplastic syndromes in neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. M. Tariq Bhatti about his paper on fingolimod-associated macular edema. Dr. Jennifer Fugate is reading our e-Pearl of the week about omega 3 fatty acids: Good for the brain. In the next part of the podcast Dr. Chafic Karam interviews Dr. Josep Dalmau about disease specific paraneoplastic disorders. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Keegan, Bhatti, Fugate, Karam and Dalmau.Dr. Keegan serves as a Section Editor for Neurology® and as Chief Editor for eMedicine and has served as a consultant for Novartis, Bionest Parners, and the FDA.Dr. Bhatti has received consultancy fees, speaker fees or honoraria from Pfizer Inc, EMD Serono, Inc., Novartis and Bayer Schering Pharma.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Dalmau serves on the editorial board of Neurology®; receives royalties from the editorial board of Up-To-Date; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc. for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award.

1) Treatment of spinocerebellar ataxia and 2) Topic of the month: Paraneoplastic syndromes in neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Cupka interviews Dr. Theresa Zesiewicz about her paper on treatment of spinocerebellar ataxia. Dr. Jennifer Fugate is reading our e-Pearl of the week about hereditary angioedema. In the next part of the podcast Dr. Chafic Karam interviews Dr. Josep Dalmau about NMDA encephalitis. Next week, you will hear the last interview by Dr. Karam with Dr. Dalmau about other paraneoplastic syndromes in neurology. The participants had nothing to disclose except Drs. Zesiewicz, Fugate, Karam and Dalmau.Dr. Zesiewicz serves on the speakers' bureau for and has received funding for travel and speaker honoraria from Teva Pharmaceutical Industries Ltd.; serves on the editorial board of Tremor and Other Hyperkinetic Movement Disorders; serves/has served as a consultant for Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Allergan, Inc., UCB, and Novartis; is listed as an inventor on a provisional patent on the use of nicotinic modulators in treating ataxia and imbalance held by the University of South Florida; and receives/has received research support from Pfizer Inc, the National Ataxia Foundation, the Friedreich's Ataxia Research Association, and the Bobby Allison Ataxia Research Center.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Dalmau serves on the editorial board of Neurology®; receives royalties from the editorial board of Up-To-Date; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc. for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award.

1) Absent brainstem reflexes and 2) Topic of the month: Paraneoplastic syndromes in neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Shin Chien Beh about his paper on a 41-year-old comatose man. Dr. Jennifer Fugate is reading our e-Pearl of the week about gait freezing. In the next part of the podcast Dr. Chafic Karam interviews Dr. Josep Dalmau about common central nervous system paraneoplastic disorders. Over the next two weeks, Dr. Karam will interview Dr. Dalmau about other paraneoplastic syndromes in neurology. The participants had nothing to disclose except Drs. Burns, Fugate, Karam and Dalmau.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Dalmau serves on the editorial board of Neurology®; receives royalties from the editorial board of Up-To-Date; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc. for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award.

1) IV thrombolysis-treated ischemic stroke patients and 2) Topic of the month: Paraneoplastic syndromes in neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Daniel Strbian about his paper on IV thrombolysis-treated ischemic stroke patients. Dr. Jennifer Fugate is reading our e-Pearl of the week about RRT autoregulation. In the next part of the podcast Dr. Chafic Karam interviews Dr. Josep Dalmau about common paraneoplastic syndromes causing central nervous system disorders. Over the following weeks, Dr. Karam will interview Dr. Dalmau about other paraneoplastic syndromes in neurology. All participants have disclosures.

Evaluation of post-cardiac arrest hypoxic-ischemic encephalopathy. Interview with Eelco Wijdicks.

1) Incidence of MCI subtype differences and 2) Topic of the month: Ethics issues. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erin Foff interviews Dr. Rosebud Roberts about her paper on the incidence of MCI subtype differences. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about pain in the ear. In the next part of the podcast Dr. Eric Adelman interviews Dr. Michael Russo about requests for medications used for cognitive enhancement. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Roberts and Clardy.Dr. Roberts receives research support from the NIH and Abbott.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.

1) AB load and cognition and 2) Topic of the month: Ethics Issues. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alberto Espay interviews Dr. Kejal Kantarci about her paper on AB load and cognition in cognitively normal older adults. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Vespers curse. In the next part of the podcast Dr. Thomas Cochrane interviews Dr. Joseph Fins about neuroimaging in disorders of consciousness. Next week you will hear our last interview regarding ethic issues. The participants had nothing to disclose except Drs. Espay, Kantarci, Clardy, Cochrane and Fins.Dr. Kantarci receives research support from the NIH.Dr. Espay serves on scientific advisory boards for Boehringer Ingelheim and Solvay Pharmaceuticals, Inc.; serves on the editorial advisory board for The European Neurological Journal; has received speaker honoraria from UCB/SCHWARZ PHARMA, Medtronic, Inc., and Novartis; has received honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society; has served on speakers' bureaus for UCB/SCHWARZ PHARMA and Novartis; receives/has received research support from Medtronic, Inc., Allergan, Inc., CleveMed, the KL2 Research Scholars mentored career development award, and NIH Institutional Clinical and Translational Science Award (RR026315-02), Dean Scholar's Award - University of Cincinnati, Davis Phinney Foundation, and the Michael J Fox Foundation. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Cochrane received royalties from the publication of the book First Aid for the Boards: Neurology.Dr. Fins serves as an editorial board member for The Oncologist and The Cambridge Quarterly, received royalties from the publication of the book A Palliative Ethic of Care: Clinical Wisdom at Life's End and serves as President of American Society for Bioethics and Humanities.

1) MuSK myasthenia and 2) Topic of the month: Ethics Issues. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Isabel Illa about her paper on the effect of rituximab in MuSK myasthenia. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Möbius syndrome. In the next part of the podcast Dr. Nandini Muralidharan interviews Dr. Michael Schneck about conflicting values in withdrawal of support. Over the next two weeks, we will have additional interviews regarding ethic issues. The participants had nothing to disclose except Drs. Burns, Illa, Clardy and Schneck.Dr. Illa has received funding for travel from Genzyme Corporation; serves on the editorial board of Neurologia; is listed as author on patent(s) re: Dysferlin detection in monocytes licensed to Athena Diagnostics, Inc.; and receives research support from Grifols, FIS (Fondo de Investigaciones Sanitarias), ISCIII, Ministry of Health (Spain), and Fundacion Gemio. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Schneck serves on data safety monitoring boards for Talecris Biotherapeutics, Chelsea Therapeutics, and Baxter International Inc.; serves on the editorial advisory boards for the Journal of Stroke and Cerebrovascular Disease and Frontiers in Neurocritical Care and Neurohospitalist Care; receives publishing royalties from Continuum; serves on the speakers' bureaus for Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Boehringer Ingelheim, and Pfizer Inc; and receives research support from NMT Medical, Schering-Plough Corp., and the NIH.

1) MRI cortical thickness biomarker and 2) Topic of the month: Ethics Issues. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Brad Dickerson about his paper on the MRI cortical thickness biomarker. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about the empty delta sign. In the next part of the podcast Dr. Alberto Espay interviews Dr. Tony Lang about placebo use for psychgenic disorders. Over the next three weeks, we will have additional interviews regarding ethic issues. The participants had nothing to disclose except Drs. Dickerson, Clardy, Espay and Lang.Dr. Dickerson serves on the editorial board of Hippocampus; serves as a consultant for Pfizer Inc; and receives research support from the NIH and the Alzheimer's Association.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves/has served on scientific advisory boards for Boehringer Ingelheim, Solvay Pharmaceuticals, Inc., and Abbott; has received honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society; serves on the editorial board of The European Neurological Journal; serves/has served on the speakers' bureaus for Novartis and UCB; and receives/has received research support from Medtronic, Inc., Allergan, Inc., CleveMed, the University of Cincinnati, the Davis Phinney Foundation, and the Michael J Fox Foundation, and is funded by the KL2 Research Scholars mentored career development award, the NIH Institutional Clinical and Translational Science Award (RR026315-02). Dr. Lang has served on scientific advisory boards for Abbott, Allon Therapeutics, Inc., Biovail Corporation, Boerhinger Ingelheim, Cephalon, Inc., Ceregene, Eisai Inc., Medtronic, Inc. Lundbeck Inc., NeuroMolecular Pharmaceuticals , Novartis, Merck Serono, Solvay Pharmaceuticals, Inc., TaroPharma, and Teva Pharmaceutical Industries Ltd.; has received speaker honoraria from GlaxoSmithKline and UCB; receives/has received research support from the Canadian Institutes of Health Research, the Dystonia Medical Research Foundation, the Michael J. Fox Foundation, the National Parkinson Foundation, and the Ontario Problem Gambling Research Centre; and has served as an expert witness in cases related to the welding industry.

1) Hemispatial neglect and 2) Topic of the month: Ethics Issues. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Giacomo Koch about his paper on hemispatial neglect. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about the trunk-thigh test of Babinski. In the next part of the podcast Dr. Farrah Mateen interviews Dr. Neelum Aggarwal about emerging issues at the intersection of neurology and applied ethics. Next week, Dr. Espay will interview Dr. Lang about placebo use for psychogenic disorders. The participants had nothing to disclose except Drs. Clardy, Mateen and Aggarwal.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Mateen served on the editorial team for the Neurology® Resident and Fellow Section from 2006 to 2009. Dr. Aggarwal has served on a scientific advisory board for Pfizer Inc; and receives research support from the NIH and the Alzheimer's Association.

Bedside Testing of the Prefrontal Lobes with interviews with Russ Swerdlow.

1) Transverse myelitis and 2) Topic of the month: Dizziness. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Bragg interviews Dr. Thomas Scott about the evidence-based guideline on transverse myelitis. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Gates' rule of 4 of the brainstem. In the next part of the podcast Dr. Ted Burns interviews Drs. Kevin Kerber and Robert W. Baloh about Dix-Hallpike maneuver. The participants had nothing to disclose except Drs. Scott, Clardy, Burns, Kerber and Baloh.Dr. Scott has received funding for travel or speaker honoraria from, served on the speakers' bureaus and scientific advisory boards of, and performed consultation work for Acorda Therapeutics Inc., Avanir Pharmaceuticals, Biogen Idec, Novartis, and Teva Pharmaceutical Industries Ltd.; served as an associate editor for BMC Neurology; and has received research support from Biogen Idec, National Multiple Sclerosis Society, Novartis, Pittsburgh Foundation, and Teva Pharmaceutical Industries Ltd.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Kerber has served as a consultant for and received speaker honoraria from the American Academy of Neurology; receives publishing royalties for Clinical Neurophysiology of the Vestibular System, 4th edition (Oxford University Press, 2010); and receives research support from the NIH/NCRR and the Agency for Healthcare Research and Quality.Dr. Baloh has received speaker honoraria from the American Academy of Neurology; serves on the editorial board of Neurology; receives publishing royalties for Clinical Neurophysiology of the Vestibular System, 4th edition (Oxford University Press, 2010); and receives research support from the NIH.

Update on stroke care. Interviews with Brett Kissela from the summer of 2011.

1) Respective epilepsy surgery and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Hamada Hamid about his paper on respective epilepsy surgery. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Post-measles central nervous system syndromes. In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about renal insufficiency with final comments on the monthly topic: hypoxic-ischemic encephalopathy. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Goodkin, Hamid, Fugate, Burns and Wijdicks.Dr. Goodkin serves on the scientific board for Tuberous Sclerosis Alliance and CURE; serves on the editorial board for Neurology and Surgical Neurology International; receives royalties from the publication of the book The choking game and other strangulation activities in children and adolescents; and is funded by NIH grants [R01 NS067439 PI and R01 NS48413 PI].Dr. Hamid serves as Managing Editor of the Journal of Muslim Mental Health and receives research support from the National EpiFellows Foundation and the Epilepsy Foundation. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

1) Practice of Neurology 2000-2010 Report and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Ms. Oksana Drogan about the Practice of Neurology 2000-2010 Report. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Ice Pack Test. In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about imaging and laboratory testing. For the last week, Dr. Burns will interview Dr. Wijdicks about take-home comments on the monthly topic. The participants had nothing to disclose except Ms. Drogan and Drs. Burns, Fugate, and Wijdicks.Ms. Drogan is a salaried employee of the American Academy of Neurology.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

1) Intravenous dihydroergotamine and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Pearce Korb interviews Dr. Peter Goadsby about his paper on intravenous dihydroergotamine. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Figure 4 sign. In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about myoclonic status. Over the following weeks, Dr. Burns will interview Dr. Wijdicks about imaging plus laboratory testing and take-home comments from topic discussed. The participants had nothing to disclose except Drs. Goadsby, Fugate, Burns and Wijdicks.Dr. Goadsby has served as a consultant for or served on a scientific advisory board for Advanced Bionics, Allergan, Inc., Almirall, Amgen, ATI, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Boston Scientific, CoLucid Pharmaceuticals, Coherex Medical, Inc., Eli Lilly & Company, GlaxoSmithKline, Johnson & Johnson, Medtronic, Inc., MAP Pharmaceuticals, Inc. (makers of an inhaled form of DHE; this consultation period post-dates the period of audit, the period of data collection and initial analysis), Minster Pharmaceuticals plc, Merck & Co., Inc., Neuralieve Inc., NeurAxon Inc., NeuroTherapeutics Pharma, and Pfizer Inc.; receives royalties from the publication of Mechanism and Management of Headache, 7th ed. (Elsevier, 2005); and has received research support from GlaxoSmithKline, Neuralieve Inc., Merck & Co., Inc., Johnson & Johnson, and MAP Pharmaceuticals, Inc. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

1) Guideline update: treatment of essential tremor and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Tiffini Voss interviews Dr. Rodger Elble about the guideline update on treatment of essential tremor. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about 'Burned-out hippocampus' syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about neurologic examination of post-cardiac arrest patients. Over the following weeks, Dr. Burns will interview Dr. Wijdicks about how to translate neurologic examination into a prognosis. The participants had nothing to disclose except Drs. Elble, Fugate, Burns and Wijdicks.Dr. Elble serves on the scientific advisory board for the International Essential Tremor Foundation; has received funding for travel from the Movement Disorders Society; receives research support from GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Pfizer Inc, Phytopharm, Janssen (Ortho-McNeil), the NIH/NINDS, and the Spastic Paralysis Research Foundation of Kiwanis International; and has acted as an expert witness in a medico-legal proceeding. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

John D. Stewart Focal Mononeuropathies Lesson of the Week Interviews (July 2011)

1) Ophelia syndrome and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennie Taylor interviews Dr. Josep Dalmau about his paper on Ophelia syndrome. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about How long must an athlete wait before returning to play after a concussion? In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about operational issues related to post-cardiac arrest patients. Over the following weeks, Dr. Burns will interview Dr. Wijdicks about neurologic evaluation of the post-cardiac arrest patient. The participants had nothing to disclose except Drs. Dalmau, Fugate, Burns and Wijdicks.Dr. Dalmau serves on the editorial board of Neurology®; receives royalties from the editorial board of Up-To-Date; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc. for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

1) Our 200th podcast and 2) Topic of the month: Neuro-ophthalmology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Jennifer Majersik about her paper on cost-effectiveness of telestroke. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week on "Which athletes are at highest risk for sports-related concussion and what are the predictors of speed of recovery?" In the next part of the podcast Dr. Chafic Karam interviews Dr. Mark Kupersmith about Apex syndrome. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Kissela, Majersik, Clardy, Karam and Kupersmith.Dr. Kissela has served on the scientific advisory board for for Allergan, Inc.; receives honoraria from Allergan, Inc; receives research support from the NIH; and gave expert testimony in medico legal cases related to stroke. Dr. Majersik receives research support from the NIH/NCI; and has provided expert testimony in a medico-legal case.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kupersmith serves as Chair of Nordic U10 EY1017281-03, received research support from Nordic U10 EY1017281-03 ECRIPS and has given expert testimony.

1) Meralgia paresthetica and 2) Topic of the month: Neuro-ophthalmology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Chris Klein about his paper on meralgia paresthetica. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week on "Is loss of consciousness required for a diagnosis of concussion?" In the next part of the podcast Dr. Chafic Karam interviews Dr. Mark Kupersmith about cranial nerve 6. Next week, Dr. Karam will interview Dr. Kupersmith about Apex syndrome. The participants had nothing to disclose except Drs. Burns, Klein, Clardy, Karam and Kupersmith.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Klein serves on the editorial board of the Journal of Peripheral Nerve Society; serves as a consultant for Pfizer Inc; and receives research support from the NIH/NINDS.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kupersmith serves as Chair of Nordic U10 EY1017281-03, received research support from Nordic U10 EY1017281-03 ECRIPS and has given expert testimony.

1) Crossed led sign and 2) Topic of the month: Neuro-ophthalmology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Berend Feddersen about his paper on favorable outcome after severe stroke. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about idiopathic orbital inflammatory syndrome. In the next part of the podcast Dr. Chafic Karam interviews Dr. Mark Kupersmith about cranial nerve 4. Over the next two weeks, Dr. Karam will interview Dr. Kupersmith about other cranial nerves involved in vision. The participants had nothing to disclose except Drs. Southerland, Feddersen, Clardy, Karam and Kupersmith.Dr. Southerland receives research support from the University of Virginia GME Office and Housestaff Council-Young Scientist Award.Dr. Feddersen received speaker honoraria from UCB and Pfizer Inc.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kupersmith serves as Chair of Nordic U10 EY1017281-03, received research support from Nordic U10 EY1017281-03 ECRIPS and has given expert testimony.

1) Cardiac arrest survivors and 2) Topic of the month: Neuro-ophthalmology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Rabinstein and Fugate about their paper on cardiac arrest survivors. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about cocaine and beta blockers. In the next part of the podcast Dr. Chafic Karam interviews Dr. Mark Kupersmith about cranial nerve 3. Over the following weeks, Dr. Karam will interview Dr. Kupersmith about other cranial nerves involved in vision. The participants had nothing to disclose except Drs. Burns, Rabinstein, Fugate, Clardy, Karam and Kupersmith.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Rabinstein serves as Section Editor for Year Book Neurology and Neurosurgery Section Editor for Neurocritical Care; has receives research support from CardioNet and Boston Scientific; and receives royalties for books published with Elsevier.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kupersmith serves as Chair of Nordic U10 EY1017281-03, received research support from Nordic U10 EY1017281-03 ECRIPS and has given expert testimony.

Sports-related Neurology, including concussion

1) Early stroke risk and ABCD2 score performance and 2) Topic of the month: Preventive neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Matthew Giles about his paper on early stroke risk and ABCD2 score performance. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about subconjunctival hemorrhages. In the next part of the podcast, Dr. Ted Burns interviews Dr. David Saperstein on B vitamin deficiencies. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Barrett, Giles, Clardy, Burns and Saperstein.Dr. Barrett serves on the editorial board of Neurology®.Dr. Giles has received funding for travel and speaker honoraria from Boehringer Ingelheim; and has received research support from National Institute of Health Research.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Saperstein serves on the scientific advisory boards for Talecris Plasma Resources, CSL Behring and Pfizer Inc; and serves on the speakers' bureau of Lilly.

1) Normal pressure hydrocephalus and 2) Topic of the month: Preventive neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Bryan Klassen about his paper on normal pressure hydrocephalus. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Hoovers sign. In the next part of the podcast, Dr. Ted Burns interviews GianPietro Sechi about deficiency of thiamine. Next week, you will hear Ted Burns interview David Saperstein on B vitamin deficiencies. The participants had nothing to disclose except Drs. Clardy and Burns.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.